Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Natalizumab para la esclerosis múltiple recurrente remitente

Información

DOI:
https://doi.org/10.1002/14651858.CD007621.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 05 octubre 2011see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esclerosis múltiple y enfermedades raras del sistema nervioso central

Copyright:
  1. Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Eugenio Pucci

    Correspondencia a: U.O. Neurologia ‐ Ospedale di Macerata, ASUR Marche ‐ Zona Territoriale 9, Macerata, Italy

    [email protected]

  • Giorgio Giuliani

    U.O. Neurologia ‐ Ospedale di Macerata, ASUR Marche ‐ Zona Territoriale 9, Macerata, Italy

  • Alessandra Solari

    Neuroepidemiology Unit, Fondazione I.R.C.C.S. ‐ Neurological Institute Carlo Besta, Milan, Italy

  • Silvana Simi

    Past Senior Researcher of Institute of Clinical Physiology, Pisa, Italy

  • Silvia Minozzi

    Department of Epidemiology, ASL RM/E, Rome, Italy

  • Carlo Di Pietrantonj

    Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi‐SeREMI ‐ Cochrane Vaccines Field, Azienda Sanitaria Locale ASL AL, Alessandria, Italy

  • Ian Galea

    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK

Contributions of authors

Pucci, Giuliani, Solari, Simi and Minozzi drafted the protocol.

Pucci developed the search strategy.

Pucci, Giuliani and Solari performed screening of identified trials for possible inclusion.

Pucci and Galea extracted data from trials.

Pucci, Minozzi and Giuliani assessed methodological quality of each included trial.

Di Pietrantonj checked the extraction, structured the comparisons, entered the data into Review Manager (RevMan) 2008 and performed the analysis.

Pucci and Di Pietrantonj interpreted the analysis.

Pucci, Giuliani, Solari, Simi, Galea, Minozzi and Di Pietrantonj wrote the final report.

Pucci and Di Pietrantonj will update the review.

Sources of support

Internal sources

  • Cochrane Vaccines Field ‐ SSEpi / SeREMI ‐ ASL Alessandria (Local Health Unit), Italy.

External sources

  • Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche, Italy.

    Travel expense reimbursement for meetings among the authors. Computer and Internet costs.

Declarations of interest

Pucci has received funds from a non‐profit association, the "Associazione Marchigiana sclerosi multipla e altre malattie neurologiche"; this association has received donations from Biogen Dompé, Merck‐Serono and Bayer‐Schering. In the last 5 years, Pucci has also received honoraria, reimbursement for attending congresses, and grant support for organising scientific activities from the above‐mentioned drug industries and from Aventis, UCB, Lundbeck and Novartis.

Solari has received research funding from Biogen Dompé and has also received consultancy payment from Merck‐Serono.

Giuliani, Di Pietrantonj, Simi, Minozzi and Galea have no conflict of interests.

Acknowledgements

We thank Deirdre Beecher, Liliana Coco and Dr. Graziella Filippini ‐ Cochrane Multiple Sclerosis Review Group.

Version history

Published

Title

Stage

Authors

Version

2011 Oct 05

Natalizumab for relapsing remitting multiple sclerosis

Review

Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj, Ian Galea

https://doi.org/10.1002/14651858.CD007621.pub2

2009 Jan 21

Natalizumab for relapsing remitting multiple sclerosis

Protocol

Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Carlo Di Pietrantonj, Silvana Simi, Silvia Minozzi, Ian Galea

https://doi.org/10.1002/14651858.CD007621

Differences between protocol and review

In the protocol, we stated that "adverse event" did not include MS relapses. In the review we included MS relapses in AEs as the original trials did. Whenever possible, however, we analysed data including and excluding MS relapses.

Incidence of serious AE was moved from secondary outcomes to primary outcomes.